Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
Статья

Prodrug-Like, PEGylated Protein Toxin Trichosanthin for Reversal of Chemoresistance

Yingzhi ChenShanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Hai-ke Rd, Shanghai 201203, ChinaMeng ZhangShanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Hai-ke Rd, Shanghai 201203, ChinaHongyue JinShanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Hai-ke Rd, Shanghai 201203, ChinaYisi TangGuangzhou University of Chinese Medicine, Tropical Medical Institute, 12 Ji-chang Rd, Guangzhou 510450, ChinaAihua WuGuangzhou University of Chinese Medicine, Tropical Medical Institute, 12 Ji-chang Rd, Guangzhou 510450, ChinaQin XuGuangzhou University of Chinese Medicine, Tropical Medical Institute, 12 Ji-chang Rd, Guangzhou 510450, ChinaYongzhuo HuangUniversity of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China
2017en
ABI

Аннотация

Multidrug resistance (MDR) is a main obstacle in cancer chemotherapy. The MDR mechanisms involve P-glycoprotein (P-gp) overexpression, abnormality of apoptosis-related protein, and altered expression of drug-targeting proteins. Therapeutic proteins are emerging as candidates for overcoming cancer MDR because of not only their large molecular size that potentially circumvents the P-gp-mediated drug efflux but also their distinctive bioactivity distinguished from small-molecular drugs. Herein we report trichosanthin, a plant protein toxin, possesses synergistic effect with paclitaxel (PTX) in the PTX-resistance A549/T nonsmall cell lung cancer (NSCLC) cells, by reversing PTX-caused caspase 9 phosphorylation and inducing caspase 3-dependent apoptosis. Moreover, via intein-mediated site-specific protein ligation, a matrix metalloproteinase (MMP)-activatable cell-penetrating trichosanthin delivery system was constructed by modification of a cell-penetrating peptide and MMP-2-sensitive PEGylation to overcome the limitation of in vivo application of trichosanthin, by improving the short half-life and poor tumor targeting, as well as immunogenicity. In a mouse model bearing A549/T tumor, the MMP-activatable trichosanthin was further tested for its application for MDR reversal in combination with PTX liposomes. The delivery system showed synergy effect with PTX-loaded liposome in treating MDR cancer in vivo.

Перевод пока недоступен

Идентификаторы

Цитирования и источники

Цитирований: 5Использованных источников: 0